title: Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study.
abstract: We tested whether zoledronic acid, a biphosphonate with proposed apoptotic activity, augmented the cytotoxicity of cisplatin and/or gemcitabine in A549 lung cancer cell line. This cell line was subjected to different concentrations of the above chemotherapeutic agents and zoledronic acid. Cytotoxicity was assessed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide) assay. Particularly, zoledronic acid in 100 micromolar (microM) concentration augmented the cytotoxicity by cisplatin 1microg/ml from 25% to 70% (Z=3.22, P=0.0072). A significant portion of cells underwent apoptosis with or without zoledronic acid, but more so with the combination treatment as assessed by an Annexin V-FITC apoptosis detection kit. However, 100microM zoledronic acid showed 50% cytotoxicity on its own, but failed to improve cytotoxicity by Gemcitabine. Thus, we show for the first time in a lung cancer cell line that zoledronic acid bears cytotoxic potential on its own and in conjunction with cisplatin. The clinical potential of this finding should be further studied.
authors.affiliation: Akdeniz University, Department of Biochemistry, Antalya, Turkey.
authors.forename: O H
authors.initials: OH
authors.lastname: Ozturk
authors.forename: H
authors.initials: H
authors.lastname: Bozcuk
authors.forename: D
authors.initials: D
authors.lastname: Burgucu
authors.forename: D
authors.initials: D
authors.lastname: Ekinci
authors.forename: M
authors.initials: M
authors.lastname: Ozdogan
authors.forename: S
authors.initials: S
authors.lastname: Akca
authors.forename: M
authors.initials: M
authors.lastname: Yildiz
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D050071:Bone Density Conservation Agents / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000633:toxicity*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D004164:Diphosphonates / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000473:pathology*; D000077211:Zoledronic Acid; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D003841:Deoxycytidine; D000077211:Zoledronic Acid; D002945:Cisplatin; D000093542:Gemcitabine